Search the Newsreel

Roche targets Novartis on IgAN market after Phase III win

Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology …

Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of …

Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof

This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about 1.0% to …

Roche, Ionis RNA drug scores in kidney disease study

Roche’s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial

Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share

Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's …

Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study

Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a …

Change in Roche’s Board of Directors

F. Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. …

Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study

Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c …

Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

F. Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c …

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain their vision with …

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and …

Roche agrees to $1bn deal with Dualitas for bispecific antibody research

Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases

F. Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and …

Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center

Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development …

Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma

Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio's label to patients who have received at least one prior systemic …

Roche’s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma

Roche, Dualitas team up to find bispecific drugs for immune diseases

Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the …

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer

F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The …

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). With the FDA granting a priority review to the sBLA, a decision from the regulatory …

Roche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD

Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

Company Logo 249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With Confidence Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, …

Why Roche Holding (SWX:ROP) Is Getting Attention Today

Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% …

Roche (SWX:ROP) Stock Looks Reasonable On Earnings But Mixed On Value

Roche Holding stock has delivered a solid multi year gain, yet the valuation signals are more mixed, which leaves investors weighing a strong price record against a less clear cut verdict on how cheap the shares really are. After a 3 year climb, the …

Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood Test

Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas. The partners plan to evaluate advanced immune based treatments aimed at improving options for lymphoma patients. Roche received FDA clearance for its Elecsys pTau217 blood test as the …

Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?

Testing for Alzheimer's-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared …

Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion

This article first appeared on GuruFocus. Roche (RHHBY), the Swiss pharmaceuticals and diagnostics giant, committed $75 million upfront for global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. Its U.S.-quoted shares fell to $53.55 Tuesday. Warning! GuruFocus has detected 7 Warning Signs with RHHBY. …

Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test

Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared …